Copyright
©The Author(s) 2020.
World J Diabetes. Jul 15, 2020; 11(7): 269-279
Published online Jul 15, 2020. doi: 10.4239/wjd.v11.i7.269
Published online Jul 15, 2020. doi: 10.4239/wjd.v11.i7.269
Parameters | EMPA-REG OUTCOME | CANVAS program | DECLARE-TIMI 58 |
Intervention | Empagliflozin/placebo | Canagliflozin/placebo | Dapagliflozin/placebo |
Median follow-up (yr) | 3.1 | 3.6 | 4.2 |
Number of patients | 7020 | 10142 | 17160 |
Prior cardiovascular disease/heart failure (%) | 99/10 | 65.6/14.4 | 40/10 |
Primary outcome (3-point MACE) | 0.86 (95%CI: 0.74-0.99) Noninferiority, P < 0.001; Superiority, P = 0.04 | 0.86 (95%CI: 0.75-0.97) Noninferiority, P < 0.001; Superiority, P = 0.02 | 0.93 (95%CI: 0.84-1.03) Noninferiority, P < 0.001; Superiority, P = 0.17 |
Cardiovascular death | 0.62 (0.49-0.77)1 | 0.87 (0.72-1.06) | 0.98 (0.81-1.17) |
Myocardial infarction | 0.87 (0.70-1.09) | 0.89 (0.73-1.09) | 0.89 (0.77-1.01) |
Stroke | 1.18 (0.89-1.56) | 0.87 (0.69-1.09) | 1.01 (0.84-1.21) |
Heart failure hospitalization | 0.65 (0.50-0.85)1 | 0.67 (0.52-0.87)1 | 0.73 (0.61-0.88)1 |
All cause mortality | 0.68 (0.57-0.82)1 | 0.87 (0.74-1.01) | 0.93 (0.82-1.04) |
Trial | Drug | Ejection fraction | Diabetic/nondiabetic |
Emperor-reduced | empagliflozin | HFrEF | Both |
Emperor-preserved | empagliflozin | HFpEF | Both |
Deliver | dapagliflozin | HFpEF | Both |
- Citation: Grubić Rotkvić P, Cigrovski Berković M, Bulj N, Rotkvić L, Ćelap I. Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure. World J Diabetes 2020; 11(7): 269-279
- URL: https://www.wjgnet.com/1948-9358/full/v11/i7/269.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i7.269